The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
Open accessAbstract
BACKGROUND: In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer. METHODS: The GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on the endpoints. External validation of the prediction based on DFS was also evaluated. RESULTS: Individual patient data from 14 randomized clinical trials that included a total of 3288 patients were analyzed. The rank correlation coefficient between DFS and OS was 0.974 (95% confidence interval [CI] = 0.971 to 0.976). The coefficient of determination between the treatment effects on DFS and on OS was as high as 0.964 (95% CI = 0.926 to 1.000), and the surrogate threshold effect based on adjusted regression analysis was 0.92. In external validation, the six hazard ratios for OS predicted according to DFS were in very good agreement with those actually observed for OS. CONCLUSIONS: DFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The validity of this approach, though not uncontroversial [13], is relatively well supported by data derived from a wide range of solid tumour settings including in colon [14], gastric [15], lung [16] and breast [17] cancers.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W., Stenning, S. P., Thompson, J. N., van de Velde, C. J. �., Nicolson, M. C., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,341
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24 · Cited by 4,519
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,470
Self-citationBang, Y., Kim, Y., Yang, H., Chung, H. C., Park, Y. K., Lee, K. H., Lee, K., Kim, Y. H., Noh, S.-I., Choi, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,712
Self-citationSasako, M., Sakuramoto, S., Katai, H., Kinoshitá, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5908 · Cited by 1,439
Self-citationRosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B. M., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6 · Cited by 1,082
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
gastric (2010) · JAMA · doi:10.1001/jama.2010.534 · Cited by 797
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Self-citationThe validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M. E., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 628
Self-citation
Cited by
Sorted by citations
Items 101–171 of 171
Song, J., Liu, L., Wang, F., & Bao, D. (2024) · Current Molecular Medicine · doi:10.2174/0115665240278762240202103722 · Cited by 7
Niu, Y.-B., Velu, P., Khalid, A., Zyoud, S. H., Kazi, M., & Li, Y. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073297703240613073134 · Cited by 7
Peng, J., Lin, J., Zeng, Z., Wu, X., Chen, G., Li, L., Lu, Z., Ding, P., Wan, D., & Pan, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.6764 · Cited by 7
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Saad, E., Coart, E., Deltuvaite-Thomas, V., Garcia-Barrado, L., Burzykowski, T., & Buyse, M. (2023) · Cancers · doi:10.3390/cancers15184669 · Cited by 8
Self-citationImamura, T., Ohgi, K., Mori, K. P., Ashida, R., Yamada, M., Otsuka, S., Uesaka, K., & Sugiura, T. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000006084 · Cited by 7
Ajani, J. A., Leung, L., Kanters, S., Singh, P., Kurt, M., Kim, I., Pourrahmat, M., Friedman, H. S., Navaratnam, P., & Reardon, G. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103934 · Cited by 6
Justifying the Choice of Endpoints for Clinical Trials
Begg, C. B. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt289 · Cited by 6
Kawashima, J., Endo, Y., Woldesenbet, S., Khalil, M., Akabane, M., Cauchy, F., Shen, F., Maithel, S. K., Popescu, I., Kitago, M., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17156-5 · Cited by 5
Korkmaz, M., Eryılmaz, M. K., Er, M. M., Koçak, M. Z., Demirkıran, A., Karaağaç, M., Araz, M., Artaç, M., & Koçak, Z. M. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00972-x · Cited by 5
Schürmann, C., & Sieben, W. (2015) · Statistics in Medicine · doi:10.1002/sim.6778 · Cited by 5
Introduction to Multivariate Survival Analysis
Emura, T., Matsui, S., & Rondeau, V. (2019) · SpringerBriefs in statistics · doi:10.1007/978-981-13-3516-7_2 · Cited by 5
Shrivastava, A., & Mishra, A. (2020) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_287_19 · Cited by 5
Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W. J., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I. L., Adhikary, R. R., et al. (2025) · Cancer · doi:10.1002/cncr.35817 · Cited by 4
Hwang, J., Ki, M. S., Kim, K.-R., Jung, S., Shim, H.-J., Bae, W., Hwang, E. C., Hur, Y. H., Jeong, O., Ryu, S. Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16301 · Cited by 4
Rim, C. H., Shin, I., Lee, H. Y., Yoon, W. S., & Park, S. (2020) · Cancers · doi:10.3390/cancers12082125 · Cited by 4
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Saad, E. D., & Buyse, M. E. (2020) · Cancers · doi:10.3390/cancers12113442 · Cited by 5
Self-citationZhang, H., Li, X., Wu, J., Zhang, J., Huang, H., Li, Y., Li, M., Wang, S., Xia, J., Qi, L., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15439 · Cited by 4
Yates, J. W. T., & Cheung, S. Y. A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.027 · Cited by 4
Tanaka, K., Kawano, M., Iwasaki, T., Itonaga, I., & Tsumura, H. (2020) · BMC Cancer · doi:10.1186/s12885-020-06871-9 · Cited by 4
Kim, T.-H., Lee, E., Lee, H. W., Ahn, M. S., Choi, Y. W., Kwon, M., Kang, S. Y., Park, B., & Choi, J.-H. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf132 · Cited by 3
Kim, Y.-J., Sung, M. K., Kim, C., Lee, J., Kim, J.-H., Sim, J., & Jeong, S.-M. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.06.007 · Cited by 3
Huan, H.-B., Wu, L., Lau, W. Y., Wen, X.-D., Zhang, L., Yang, D., Wang, X.-S., Bie, P., & Xia, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18853 · Cited by 3
Immunotherapy use in oesophagogastric cancers—a review of the literature
Smith, A., Roy, A. C., Karapetis, C. S., Broadbridge, V. T., & Price, T. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01751-4 · Cited by 3
Kang, Y.-K., Kim, H.-D., Ryu, M.-H., & Noh, S. H. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02043 · Cited by 3
Ishida, H., Sunakawa, Y., Kodera, Y., Yoshida, K., Kochi, M., Kakeji, Y., Sano, T., Takeuchi, M., Ichikawa, W., & Fujii, M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115322 · Cited by 2
Oncological impact of unexpected horizontal tumour spread in oesophagogastric junction cancer
Hu, Q., Ohashi, M., Ri, M., Makuuchi, R., Irino, T., Hayami, M., Sano, T., & Nunobe, S. (2025) · BJS Open · doi:10.1093/bjsopen/zraf119 · Cited by 2
Lee, A. R., Bae, J.-M., Choi, M. G., An, J. Y., Kim, E., & Park, B. (2025) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2025.25.e43 · Cited by 2
Laparoscopic and Robotic Surgery for Rectal Cancer—Comparative Study Between Two Centres
Dulskas, A., Albandar, M. H., Samalavičius, N. E., Han, Y. D., & Kim, N. K. (2020) · Indian Journal of Surgery · doi:10.1007/s12262-020-02287-8 · Cited by 2
Hikage, M., Fujiya, K., Kamiya, S., Tanizawa, Y., Bando, E., Notsu, A., & Terashima, M. (2022) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02397-1 · Cited by 2
Михайловна, Д. А., Поспехова, Н. И., Строганова, А. М., Golovina, D. A., Nikulin, M. P., Kalinin, A. E., Nikolaev, S. E., Stilidi, I. S., & Lyubchenko, L. N. (2023) · Molecular Biology · doi:10.1134/s0026893323010041 · Cited by 2
Confidence interval for normal means in meta-analysis based on a pretest estimator
Taketomi, N., Chang, Y.-T., Konno, Y., Mori, M., & Emura, T. (2023) · Japanese Journal of Statistics and Data Science · doi:10.1007/s42081-023-00221-2 · Cited by 2
Quelles exigences pour qu'un biomarqueur puisse être un critère de substitution acceptable ?
Paolettí, X., Rotolo, F., & Michiels, S. (2016) · Bulletin du Cancer · doi:10.1016/s0007-4551(16)30147-3 · Cited by 2
Self-citationOutstanding issues in perioperative chemotherapy for gastric cancer
Игоревна, Д. Т., Болотина, Л. В., Golubev, P. V., Kornietskaya, A. L., Ruban, M. D., & Феденко, А. А. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-529 · Cited by 1
Blasco, A., López‐Tarruella, S., Urruticoechea, A., Carrasco, E., Spera, G., Martín, M., Bermejo, B., Chap, L. I., Ruíz‐Borrego, M., Crown, J. P., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf263 · Cited by 1
Okui, J., Besselink, M. G., Wei, A. C., O'Reilly, E. M., Koerkamp, B. G., Ceuppens, S., Dekker, E. N., Paniccia, A., Zureikat, A. H., Tzeng, C.-W. D., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20620-5 · Cited by 1
Oba, K., & Paolettí, X. (2017) · Springer eBooks · doi:10.1007/978-981-10-0126-0_12 · Cited by 1
Self-citationМихайловна, Д. А., Поспехова, Н. И., Строганова, А. М., Golovina, D. A., Nikulin, M. P., Kalinin, A. E., Nikolaev, S. E., Stilidi, I. S., & Lyubchenko, L. N. (2023) · Molecular Biology · doi:10.31857/s0026898423010044 · Cited by 1
Ortiz, Y. G., Fareli, C. J., Gallegos, V., & Hernández, E. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.04.002 · Cited by 1
Emura, T., & Chen, Y. (2018) · SpringerBriefs in statistics · doi:10.1007/978-981-10-7164-5_1 · Cited by 1
Adam, R. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3513-0 · Cited by 1
Yoshikawa, T., Terashima, M., & Mizusawa, J. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01526-1 · Cited by 1
Magenkarzinom: Krankheitsfreies Überleben als Ersatz für Gesamtüberleben?
Berndt, C., & Möhler, M. (2014) · Im Focus Onkologie · doi:10.1007/s15015-014-1008-2
Overview of Oncology Drug Development
Malik, L., & Weitman, S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_1
Chirurgische Therapieoptionen bei peritonealer Metastasierung
Rau, B., Pachmayr, E., Brandl, A., & Raué, W. (2017) · Springer eBooks · doi:10.1007/978-3-662-53188-4_19
Indikation von CRS und HIPEC beim peritoneal metastasierten Magenkarzinom
Rau, B., Pachmayr, E., Thuss-Patience, P. C., & Brandl, A. (2018) · Springer eBooks · doi:10.1007/978-3-662-54500-3_20
Indication of CRS and HIPEC in Gastric Cancer-Related Peritoneal Metastasis
Rau, B., Pachmayr, E., Thuss-Patience, P. C., Garg, P. K., Gléhen, O., & Brandl, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-62640-2_20
Rajappa, S. J., & Nusrath, S. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1739189
Adenocarcinoma gástrico localmente avanzado diagnóstico y tratamiento
Malet, M. V., & ́andez, Á. C. F. ́. (2021) · Cirugía del Uruguay/Cirugía del Uruguay · doi:10.31837/relatos/10
Molenberghs, G. (2015) · Wiley StatsRef: Statistics Reference Online · doi:10.1002/9781118445112.stat00324.pub2
Emura, T., Matsui, S., & Rondeau, V. (2019) · SpringerBriefs in statistics · doi:10.1007/978-981-13-3516-7_1
Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195924
Liu, N., Wu, Y., Cheng, W., Wu, Y., Wang, L., & Zhuang, L. (2021) · Figshare · doi:10.6084/m9.figshare.14490337
Liu, N., Wu, Y., Cheng, W., Wu, Y., Wang, L., & Zhuang, L. (2021) · Figshare · doi:10.6084/m9.figshare.14490334
Survival Analysis Without Sharing of Individual Patient Data by Using a Gaussian Copula
Bonofiglio, F. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2415
Evaluation of Time-to-event Surrogate Endpoint Endpoint ─Meta-analytic Approach─
Emura, T., & Oba, K. (2024) · Japanese Journal of Biometrics · doi:10.5691/jjb.45.67
Self-citationChen, W., Cai, Z., Li, J., Li, Z., Xu, Z., Wu, J., Liu, F., Zhao, H., & Xu, Y. (2025) · Surgery · doi:10.1016/j.surg.2025.109290
Anyaduba, U. L., Orababa, O. Q., Faye, Z., Rashid, N., Shafrin, J. T., & Reardon, G. (2025) · Cancer Reports · doi:10.1002/cnr2.70195
Sternberg, C. N., Squifflet, P., Saad, E. D., Burdett, S., Fisher, D., Kurt, M., Teitsson, S., May, J. R., Patel, M. Y., Stoeckle, M., et al. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.07.013
Self-citationTang, X., & Trinquart, L. (2025) · Clinical Trials · doi:10.1177/17407745251377734
Surgical treatment of gastric cancer: A single center’s 15-year experience
Ramos, M. F. K. P., Pereira, M. A., Dias, A. R., Yagi, O. K., Nigro, B. D. C., Victor, C. R., Panichella, J. D., Zampieri, P. F., Gregorio, J. V. A. M., Maluf‐Filho, F., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100828
Tanaka, K., Kawano, M., Iwasaki, T., Itonaga, I., & Tsumura, H. (2020) · Figshare · doi:10.6084/m9.figshare.12258092
Liu, N., Wu, Y., Cheng, W., Wu, Y., Wang, L., & Zhuang, L. (2021) · Figshare · doi:10.6084/m9.figshare.14490331
Tanaka, K., Kawano, M., Iwasaki, T., Itonaga, I., & Tsumura, H. (2020) · Figshare · doi:10.6084/m9.figshare.12258101
Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point?
Shitara, K. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02767
Self-citationTripathy, A., Vishwakarma, G. K., & Bhattacharjee, A. (2026) · Statistical Papers · doi:10.1007/s00362-026-01816-z
Squifflet, P., Saad, E. D., Kurt, M., Larkin, J., Mohr, P., Moshyk, A., & Buyse, M. E. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016440
Self-citationAutomated detection of gastroesophageal adenocarcinoma recurrence from electronic health records
Okui, J., Lyu, H. G., Prakash, L. R., Li, J. J., Blum-Murphy, M. A., Ajani, J. A., Hofstetter, W. L., Rice, D. C., Mansfield, P. F., Swisher, S. G., et al. (2026) · Diseases of the Esophagus · doi:10.1093/dote/doag109
Metadata
- Authors
- Oba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., Ohashi, Y., Pignon, J.-P., Rougier, P., Sasako, M., Sakamoto, J., Sargent, D., Shitara, K., Cutsem, E. V., Buyse, M., & Burzykowski, T.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-09
- Volume
- 105
- Issue
- 21
- Pages
- 1600-1607
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC4202244
- OpenAlex
- W2168202113
- Cited by
- 168
- References
- 33
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 11 · 2023: 15 · 2022: 12 · 2021: 22 · 2020: 12 · 2019: 16 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 12 · 2014: 8 · 2013: 3
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- GlaxoSmithKline
- Institut National Du Cancer
- Japan Society for the Promotion of Science (25461577)
- National Cancer Institute (U10CA021115, P30CA015083)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- gastric cancer, disease-free survival, overall survival, surrogate endpoints, adjuvant chemotherapy, curative resection, endpoint correlation, external validation, individual patient data, cytotoxic drugs
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Cost-Benefit Analysis, Drug Administration Schedule, Gastrectomy, Humans, Stomach Neoplasms, Time Factors, Linear Models, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
